Pulmatrix (PULM) Retained Earnings (2014 - 2026)
Pulmatrix (PULM) posted Retained Earnings of -$303.5 million for Q1 2026, down 199.14% sequentially from $306.1 million in Q4 2025, and down 1.51% YoY from -$308.2 million in Q1 2025.
Pulmatrix (PULM) Retained Earnings (2014 - 2026) Analysis & Trends
Pulmatrix has reported Retained Earnings for 13 years, with the latest figure at -$303.5 million in Q1 2026.
- Quarterly Retained Earnings fell 1.51% year-over-year to -$303.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$303.5 million (down 1.51% YoY) and the FY2025 annual result came in at $306.1 million, changed 0.01% from the prior year.
- Retained Earnings declined to -$303.5 million in Q1 2026 per PULM's latest filing, from $306.1 million in the prior quarter.
- Over five years, Retained Earnings peaked at $306.1 million in Q4 2025 and troughed at -$303.5 million in Q1 2026.
- A 5-year average of -$8.4 million and a median of -$259.6 million in 2022 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2025: Retained Earnings surged 221.43% in 2022, then sank 197.77% in 2025.
- Over 5 years, Retained Earnings stood at -$273.5 million in 2022, then soared by 211.74% to $305.6 million in 2023, then grew by 0.17% to $306.1 million in 2024, then rose by 0.01% to $306.1 million in 2025, then slumped by 199.14% to -$303.5 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$303.5 million, $306.1 million, and -$301.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.60 Bn | 130.75 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.93 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.06 Bn | 59.88 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 56.22 Bn | 51.08 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.65 Bn | 28.34 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 4.38 Bn |
| 10 | Pulmatrix | 5.62 Mn | 5.62 Mn | - | 306.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 306.12 Mn |
| Mar 31, 2026 | -303.49 Mn |
| Dec 31, 2025 | 306.13 Mn |
| Sep 30, 2025 | -301.39 Mn |
| Jun 30, 2025 | 306.12 Mn |
| Mar 31, 2025 | -298.96 Mn |
| Dec 31, 2024 | 306.10 Mn |
| Sep 30, 2024 | -295.17 Mn |
| Jun 30, 2024 | -292.58 Mn |
| Mar 31, 2024 | 305.79 Mn |
| Dec 31, 2023 | 305.59 Mn |
| Sep 30, 2023 | 305.40 Mn |
| Jun 30, 2023 | -281.74 Mn |
| Mar 31, 2023 | -277.92 Mn |
| Dec 31, 2022 | -273.48 Mn |
| Sep 30, 2022 | 304.31 Mn |
| Jun 30, 2022 | 302.65 Mn |
| Mar 31, 2022 | -259.61 Mn |
| Dec 31, 2021 | -254.64 Mn |
| Sep 30, 2021 | -250.61 Mn |